Method and composition for hyperthermally treating cells
View Patent ↗A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method is administered in combination with localized internal ionizing radiation therapy.
1. A method of simultaneously providing localized internal ionizing radiation therapy in combination with thermal therapy to a target site in a patient in need thereof, the method comprising
administering to the patient a composition of nanoparticles, the nanoparticles containing at least one radioactive isotope and coated with anti-tumor antibodies, the nanoparticles forming an antibody labeled nanoparticle-cell complex at a target site, the radioactive nanoparticle resulting in radiation therapy at a dose sufficient to damage tumor-associated vessels at the localized target site, and
administering localized thermal therapy at the target site essentially simultaneously during the radiation therapy in the absence of an ultrasound contrast agent by
exposing the target site to an energy source to generate a photoacoustic signal producing conditions at the target site sufficient to heat the nanoparticle-cell complex to hyperthermally treat cells wherein the hyperthermal treatment damages or kills cells at the target site.
2. The method of claim 1 where thermal therapy is administered under conditions sufficient to result in
a first temperature at the tumor site of at least 37° C. to 43° C., and
thereafter a second temperature at the tumor site of at least one of 43° C. to 58° C., 43° C. to 45° C., 43° C. to 58° C., 45° C. to 50° C., 50° C. to 58° C., 58° C. to 60° C., greater than 58° C., or greater than 60° C., the thermal therapy resulting in thermal damage to tumor cells.
3. The method of claim 1 where the target is a tumor site.
4. The method of claim 1 where the target is neovascularization tissue.
5. The method of claim 4 where the target is endothelial cells in new blood vessels in a patient with exudative age related macular degeneration.
6. The method of claim 1 wherein the radioactive nanoparticle is a magnetic, diamagnetic, ferromagnetic, non-ferromagnetic and/or paramagnetic nanoparticle.
7. The method of claim 1 wherein the antitumor antibody is coated on or conjugated with the radioactive nanoparticle.
8. The method of claim 1 wherein the composition is administered intravenously.
9. The method of claim 1 wherein the radioactive isotope is an α-emitting isotope, a β-emitting isotope, or a combination thereof.
10. The method of claim 9 wherein the isotope is selected from the group consisting of At 211 , Ac 225 , Bi 212 , Bi 213 , Ra 223 , Pb 212 , Tb 149 , I 131 , Cu 64 , I 131 , Bi 213 , and Bi 212 .
11. The method of claim 9 wherein the dose of the isotope ranges from 10 μCi to 20,000 μCi.
12. The method of claim 1 wherein thermal therapy is applied with a controlled energy source.
13. The method of claim 1 wherein the thermal therapy is provided by at least one of electromagnetic radiation, ultrasound energy, or alternating magnetic field.
14. The method of claim 1 performed on the patient receiving at least one of chemotherapy, radiation therapy, anti-vascular endothelial growth-factor therapy, or steroid therapy.
15. The method of claim 1 wherein the target is imaged while administering thermal therapy.
16. The method of claim 1 wherein the target is imaged by at least one of thermal imaging, photoacoustic imaging, X-ray imaging, optical coherence tomography, ultrasound imaging, fluorescence imaging, chemiluminescent imaging, positron imaging, surface enhanced Raman spectroscopy, and/or magnetic resonance imaging while administering thermotherapy.
17. The method of claim 1 wherein the temperature rise at the target is regulated via a processor by a photoacoustic system or by magnetic resonance imaging.
18. A method of providing therapy to a patient having exudative age related macular degeneration, the method comprising
administering a radioactive nanoparticle-anti-tumor surface ligand or receptor antibody composition to the patient, the nanoparticles forming a labeled nanoparticle-cell complex at a localized site, the radioactive nanoparticle providing radiation therapy at a dose sufficient to damage endothelial cells of neovasculature tissues at the localized site, and
thereafter administering localized thermotherapy at the localized site essentially simultaneously during the radiation therapy in the absence of an ultrasound contrast agent by
exposing the localized site to an energy source to generate a photoacoustic signal producing conditions at the localized site sufficient to heat the nanoparticle-cell complex to hyperthermally treat cells wherein the hyperthermal treatment damages or kills cells at the localized site.